Elevation Oncology, Inc. (NASDAQ:ELEV) Receives $3.39 Consensus Price Target from Analysts
Elevation Oncology, Inc. (NASDAQ:ELEV – Get Free Report) has been assigned an average rating of “Hold” from the ten brokerages that are presently covering the stock, Marketbeat.com reports. Seven investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average twelve-month price objective among […]
Elevation Oncology, Inc. (NASDAQ:ELEV – Get Free Report) has been assigned an average rating of “Hold” from the ten brokerages that are presently covering the stock, Marketbeat.com reports. Seven investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average twelve-month price objective among […]
